Ventrix

Executive Summary

Ventrix is a private regenerative medicine company headquartered in San Diego, founded in 2013, focused on harnessing the power of extracellular matrix (ECM) to develop therapies for cardiovascular and other tissue repair indications. ECM serves as the natural scaffolding that guides cell behavior, including proliferation, differentiation, and survival. Ventrix's proprietary platform leverages tissue-specific ECM compositions to recreate the native microenvironment, aiming to promote functional tissue regeneration. Although the company remains in a relatively early stage with no disclosed pipeline details or funding history, its technology addresses a significant unmet need in cardiovascular disease, where current treatments often fail to restore damaged tissue. With a strong scientific foundation and a focus on a high-impact area, Ventrix is positioned to advance its lead candidates toward preclinical and early clinical development.

Upcoming Catalysts (preview)

• Q2 2027Initiation of First-in-Human Study for Lead ECM Product40% success
• Q4 2026Strategic Partnership or Licensing Deal with Major Pharma30% success
• Q3 2026Series B or Later-Stage Financing Round50% success